USD0.000æéå€ååŒÂ  (ET)
46.36MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
0.431å§å€
0.439é«å€
10.91Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
0.01%売買å転ç
0.430忥çµå€
0.430å®å€
3.25K売買代é
æå€±é¡æ ªäŸ¡åçç
3.57PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-69.34%ç·è³ç£å©çç
1.95052é±é«å€
0.84åºæ¥é«æ¯ç%
-24.71MçŽå©ç
104.62Mæ ªåŒæ°
-0.29141æ ªåœããå©çïŒEPSïŒ
--ããŒã¿å€
-168.66%èªå·±è³æ¬å©çç
0.36252é±å®å€
2.02%æ¯ãå¹
100.00%ç²å©çç
46.36MæäŸ¡ç·é¡
-1.19ãªã¹ã¯ãªã¿ãŒã³
7.49%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Impact Biomedical Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž211äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããåç€Ÿã®æ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯éå»1ãæéã§äœèª¿ã§ããããã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ãåæ§ã«åŒ±ãç¶æ
ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Impact Biomedical Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Impact Biomedical Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Impact Biomedical Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
ææšî
ææš
売ã(2)
äžç«(4)
è²·ã(1)
ç§»åå¹³å
売ã(5)
äžç«(0)
è²·ã(1)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Impact Biomedical Incã®äŒæ¥æ
å ±î
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
äŒæ¥ã³ãŒãIBO
äŒæ¥åImpact Biomedical Inc
æé«çµå¶è²¬ä»»è
ãCEOãHeuszel (Frank D)
ãŠã§ããµã€ãhttps://www.impactbiomedinc.com/
æ ªäž»çµ±èšî
ãããã質å
Impact Biomedical IncïŒIBOïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îImpact Biomedical IncïŒIBOïŒã®çŸåšã®æ ªäŸ¡ã¯0.43ã§ãã
Impact Biomedical Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îImpact Biomedical Incã®ãã£ãã«ãŒã·ã³ãã«ã¯IBOã§ãã
Impact Biomedical Incã®52é±é«å€ã¯ãããã§ããïŒ
îImpact Biomedical Incã®52é±é«å€ã¯1.95ã§ãã
Impact Biomedical Incã®52é±å®å€ã¯ãããã§ããïŒ
îImpact Biomedical Incã®52é±å®å€ã¯0.36ã§ãã
Impact Biomedical Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îImpact Biomedical Incã®æäŸ¡ç·é¡ã¯45.45Mã§ãã
Impact Biomedical Inc (IBO) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îImpact Biomedical IncïŒIBOïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.38ã§ãã